Americana Partners LLC Takes Position in Sight Sciences, Inc. $SGHT

Americana Partners LLC acquired a new stake in shares of Sight Sciences, Inc. (NASDAQ:SGHT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 863,918 shares of the company’s stock, valued at approximately $3,568,000. Americana Partners LLC owned approximately 1.67% of Sight Sciences as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC raised its position in Sight Sciences by 70.2% in the second quarter. CWM LLC now owns 7,607 shares of the company’s stock valued at $31,000 after purchasing an additional 3,137 shares during the last quarter. Bank of Montreal Can acquired a new position in shares of Sight Sciences in the second quarter valued at approximately $49,000. Vanguard Personalized Indexing Management LLC raised its holdings in Sight Sciences by 38.9% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock valued at $66,000 after buying an additional 4,453 shares during the last quarter. Rhumbline Advisers boosted its position in Sight Sciences by 9.5% during the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock worth $120,000 after buying an additional 4,319 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in Sight Sciences during the 1st quarter worth approximately $128,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Sight Sciences Price Performance

Shares of NASDAQ SGHT opened at $6.52 on Tuesday. The firm’s 50-day moving average price is $4.07 and its 200-day moving average price is $3.85. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $6.60. The firm has a market capitalization of $341.43 million, a P/E ratio of -7.24 and a beta of 2.47. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The firm had revenue of $12.54 million during the quarter. Equities research analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Lake Street Capital boosted their price objective on shares of Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Wall Street Zen raised Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Thursday, August 28th. Citigroup decreased their price target on Sight Sciences from $4.50 to $4.00 and set a “neutral” rating for the company in a research note on Tuesday, October 7th. Finally, Piper Sandler raised their price objective on Sight Sciences from $4.00 to $5.00 and gave the stock a “neutral” rating in a research report on Friday. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $5.17.

Insider Buying and Selling

In related news, insider Jeremy B. Hayden sold 9,731 shares of the stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $3.27, for a total value of $31,820.37. Following the transaction, the insider directly owned 256,590 shares in the company, valued at $839,049.30. This trade represents a 3.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Paul Badawi sold 24,441 shares of Sight Sciences stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $3.34, for a total transaction of $81,632.94. Following the completion of the sale, the chief executive officer directly owned 5,962,502 shares of the company’s stock, valued at approximately $19,914,756.68. The trade was a 0.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 40,796 shares of company stock worth $135,173 over the last ninety days. 30.90% of the stock is owned by insiders.

Sight Sciences Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.